Probody® therapeutics are designed to outsmart cancer by exploiting the unique conditions of the tumor microenvironment by localizing treatment in the tumor and limiting activity in healthy tissue. We design Probody therapeutics to mask its target binding region. This mask reduces activity and toxicity in healthy tissue. Our novel therapeutics take advantage of the high levels of protease activity in the tumor microenvironment. Their target-binding regions are masked to limit activity —and toxicity— in healthy tissue. When Probody therapeutics encounter active proteases near tumor tissue, the mask is designed to be removed so that the unmasked therapeutic can bind to the tumor target.
We believe our Probody therapeutics have the potential to:
- Create or widen therapeutic window – the balance between a therapy’s dose that is effective without causing unacceptable toxicity
- Enable new combinations of drugs previously not possible due to toxicities
- Expand the universe of viable therapeutic targets by opening “undruggable” target space
- Make new treatment options possible for more patients
More information about protease biology can be found in our fact sheet.